ITI Pharma and Healthcare Fund Direct Growth

Equity
Direct
Sector - Healthcare
ITI Pharma and Healthcare Fund Direct Growth

About the Fund

ITI Pharma and Healthcare Fund Direct Growth is an equity fund. This fund was started on 11 November, 2021. The fund is managed by . The fund could potentially beat inflation in the long-run.

Key Parameters

  1. ITI Pharma and Healthcare Fund Direct Growth has ₹157 Cr worth of assets under management (AUM) as on May 2024 and is less than category average.
  2. The fund has an expense ratio 0.4.

Returns

ITI Pharma and Healthcare Fund Direct Growth has given a CAGR return of 16.65% since inception. Over the last 1 year the fund has given a CAGR return of 45.67%.

Holdings

ITI Pharma and Healthcare Fund Direct Growth has allocated its funds majorly in Cash Equivalent, Health, Basic Materials. Its top holdings are Sun Pharmaceuticals Industries Ltd, Dr Reddy's Laboratories Ltd, Lupin Ltd, Max Healthcare Institute Ltd Ordinary Shares, Apollo Hospitals Enterprise Ltd

Taxation

As it is a sector - healthcare mutual fund the taxation is as follows:
For short term (less than a year) capital gains will be taxed at 15%
For long term (more than 1 year) capital gains will be taxed at 10% without indexation benefit
Dividends will always be taxed at slab rate. Gains upto Rs 1 lakh are exempt in case of long term.

Investment objective of ITI Pharma and Healthcare Fund Direct Growth

The investment objective of the scheme is to seek to generate long term capital appreciation through investing in equity and equity related securities of companies engaged in Pharma and Healthcare. However, there can be no assurance that the investment objective of the scheme would be achieved.

Minimum Investment and lockin period

Minimum investment for lump sum payment is INR 5000.00 and for SIP is INR 500.00. ITI Pharma and Healthcare Fund Direct Growth has no lock in period.

Fund Performance
zero opening, trading, fund transfer fee
71 people have invested ₹ 1.3L in ITI Pharma and Healthcare Fund Direct Growth in the last three months

Fund Overview

Expense ratio
Expense ratio
0.43%
Benchmark
Benchmark
S&P BSE Healthcare PR
AUM
AUM
₹157 Cr
Inception Date
Inception Date
11 November, 2021
Min Lumpsum/SIP
Min Lumpsum/SIP
₹5000/₹500
Exit Load
Exit Load
1%
Lock In
Lock In
No Lock-in
TurnOver
TurnOver
22.62%

Fund Distribution
as on (31-May-24)

  • Equity 99.5%

  • Debt & Cash 0.5%

Large cap
39.3%

Small cap
32.2%

Mid cap
28%

Sector Allocation

May'24

Apr'24

Mar'24

Health
97.2%
Basic Materials
2.8%
All changes are between Mar'24 and May'24

Returns for the month of May

  • Gainers

  • Losers

ITI Pharma and Healthcare Fund Direct Growth Highlights

Risk meter
pointer

Very High Risk

Investors understand that their principal will be at Very High Risk
About the fund

About the fund

This fund has delivered an average annual returns of 16.65% since inception which is less than its category average return of 21.53%
Fund Allocations

Fund Allocations

This fund has an allocation of 99.5% in Equity, 0% in Debt and 0.5% in Cash related instruments
AUM size ₹157 Cr

AUM size ₹157 Cr

This fund has AUM of ₹157 Cr which is less than its category average of ₹ 1665 Cr
Expense Ratio 0.43%

Expense Ratio 0.43%

This fund has an expense ratio of 0.43% which is less than its category average expense ratio of 1.45%

Frequently Asked Questions

The current NAV of ITI Pharma and Healthcare Fund Direct Growth is ₹14.91 as on 14-Jun-2024.
Existing (Absolute + CAGR) as on 14-Jun-2024.
ITI Pharma and Healthcare Fund Direct Growth
Absolute Returns
CAGR Returns
1 Month Returns
4.94%
4.94%
6 Month Returns
20.39%
20.39%
1 Year Returns
45.67%
45.67%
3 Years Returns
0%
0%
5 Years Returns
0%
0%
With INDmoney, the process of investing is very simple and involves zero commission.
  • Click Buy on the fund name.
  • Input the amount you are looking to invest.
  • Select Lump Sum or SIP (Weekly, Monthly or Quarterly).
  • Select your bank account and proceed with Payment.
0.43% as on May 2024
₹157 Cr as on May 2024
Sun Pharmaceuticals Industries Ltd(15.87%), Dr Reddy's Laboratories Ltd(7.24%), Lupin Ltd(6.19%), Max Healthcare Institute Ltd Ordinary Shares(5.69%), Apollo Hospitals Enterprise Ltd(4.82%) as on May 2024
The alpha ratio for the ITI Pharma and Healthcare Fund Direct Growth for various period is as follows:
Fund Name
Alpha 1 Year
Alpha 3 Years
Alpha 5 Years
ITI Pharma and Healthcare Fund Direct Growth
2.04
-
-
As on May 2024
The alpha for ITI Pharma and Healthcare Fund Direct Growth is calculated against S&P BSE Healthcare PR. Higher alpha indicates that this fund has generated extra returns compared to the benchmark index. An alpha of 1.0 means the fund has outperformed its benchmark index by 1%.
The Beta ratio for the ITI Pharma and Healthcare Fund Direct Growth for various period is as follows:
Fund Name
Beta 1 Year
Beta 3 Years
Beta 5 Years
ITI Pharma and Healthcare Fund Direct Growth
0.84
-
-
As on May 2024
The Beta for ITI Pharma and Healthcare Fund Direct Growth is calculated with S&P BSE Healthcare PR. Beta tells the volatility of the mutual fund relative to its benchmark. If the beta of a mutual fund is more than 1, then the mutual fund is more volatile than its benchmark. If beta is less than 1, then the mutual fund is less volatile than the benchmark.
The sharpe ratio for the ITI Pharma and Healthcare Fund Direct Growth for various period is as follows:
Fund Name
Sharpe Ratio 1 Year
Sharpe Ratio 3 Years
Sharpe Ratio 5 Years
ITI Pharma and Healthcare Fund Direct Growth
1.99
-
-
As on May 2024
The sharpe ratio for ITI Pharma and Healthcare Fund Direct Growth is calculated with S&P BSE Healthcare PR. Sharpe ratio tells risk-adjusted-returns of the mutual fund. The higher a fund's Sharpe ratio, the better a fund's returns have been relative to the risk it has taken on.
The standard deviation for the ITI Pharma and Healthcare Fund Direct Growth for various period is as follows:
Fund Name
Standard Deviation 1 Year
Standard Deviation 3 Years
Standard Deviation 5 Years
ITI Pharma and Healthcare Fund Direct Growth
14.44
-
-
As on May 2024
Standard deviation tells the volatility of the returns of the mutual fund. The higher a fund's Standard deviation, the higher the volatility of the fund's returns.
The Exit load of ITI Pharma and Healthcare Fund Direct Growth is 1%